Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Liabilities and Shareholders Equity (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $5.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 37.01% year-over-year to $5.1 million, compared with a TTM value of $23.1 million through Sep 2025, down 37.66%, and an annual FY2024 reading of $6.9 million, down 34.92% over the prior year.
  • Liabilities and Shareholders Equity was $5.1 million for Q3 2025 at Xenetic Biosciences, down from $5.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $13.7 million in Q1 2023 and bottomed at $5.1 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 3 years is $9.0 million, with a median of $9.0 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity dropped 29.15% in 2024, then plummeted 40.73% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $10.6 million in 2023, then tumbled by 34.92% to $6.9 million in 2024, then decreased by 26.57% to $5.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for XBIO at $5.1 million in Q3 2025, $5.4 million in Q2 2025, and $5.8 million in Q1 2025.